New immune therapy tested to boost stem cell transplant success for tough lymphomas
NCT ID NCT07387848
Summary
This study is testing a new immune-based drug called glofitamab for adults with an aggressive type of lymphoma (DLBCL) that has returned or not responded to initial chemotherapy. The goal is to see if using glofitamab before and/or after a stem cell transplant can help control the cancer better and improve survival. The study will enroll about 40 participants who are medically fit for a transplant and will closely monitor how well the treatment works and its side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA REFRACTORY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.